Frontier Medicines Corporation
151 Oyster Point Blvd.
2nd Floor
South San Francisco
California
94080
United States
Tel: 650-457-1005
Website: https://frontiermeds.com/
Email: contact@frontiermeds.com
25 articles with Frontier Medicines Corporation
-
Frontier Medicines to Spotlight Lead Candidate, Novel Dual KRASG12C Inhibitor FMC-376, and the Frontier™ Platform at the 2023 AACR Annual Meeting
3/14/2023
Frontier Medicines Corporation today announced upcoming presentations featuring preclinical data on its novel dual KRASG12C inhibitor FMC-376 and advances from the Frontier™ Platform.
-
Frontier Medicines Expands Leadership Team with Addition of Christo Shalish as Head of Business Development
2/28/2023
Frontier Medicines Corporation announced the addition of Christo Shalish to the leadership team as senior vice president and head of business development.
-
Frontier Medicines Announces Advancement of Second and Third Programs Under Global Partnership with AbbVie
1/5/2023
Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthroughs against otherwise undruggable disease-causing targets, announced the second and third programs under the company's global partnership with AbbVie have advanced into lead generation.
-
Frontier Medicines Advances First Development Candidate, FMC-376, a Uniquely Differentiated Inhibitor of Both Active and Inactive KRASG12C, into IND-Enabling Studies
1/5/2023
Frontier Medicines Corporation announced the selection of its first development candidate, FMC-376, an oral, covalent small-molecule inhibitor that selectively targets both active (GTP-bound) and inactive (GDP-bound) conformations of KRASG12C.
-
Frontier Medicines to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/4/2023
Frontier Medicines Corporation today announced that Chris Varma, Ph.D., Frontier’s co-founder, chairman, and CEO, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 10:00 a.m. PT.
-
Frontier Medicines to Present at Credit Suisse 31st Annual Healthcare Conference
11/1/2022
Frontier Medicines Corporation announced that Chris Varma, Ph.D., Frontier’s co-founder, chairman, and CEO, will participate in a fireside chat at the Credit Suisse 31st Annual Healthcare Conference at 9:10 a.m. PT on November 8, 2022 in Rancho Palos Verdes, CA.
-
This week's Movers & Shakers includes Tessa and Adial bringing in new CEOs, while other companies strengthened their regulatory and medical teams with key appointments
-
Frontier Medicines Announces the Appointment of Seasoned Legal Executive Mark Dizon, J.D., as General Counsel
8/25/2022
Frontier Medicines Corporation today announced the appointment of Mark Dizon, J.D., to the position of general counsel.
-
Frontier Medicines Announces Distinguished Oncologist Dr. Pasi Jänne Joins its Scientific Advisory Board
7/14/2022
Frontier Medicines Corporation today announced the appointment of Pasi A. Jänne, M.D., Ph.D., director of the Lowe Center for Thoracic Oncology and director of the Belfer Center for Applied Cancer Science at Dana-Farber Cancer Institute, to its Scientific Advisory Board (SAB).
-
Frontier Medicines to Present at the Jefferies Healthcare Conference
6/2/2022
Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthroughs against otherwise undruggable disease-causing targets, today announced that Chris Varma, Ph.D., Frontier’s co-founder, chairman, and CEO, will present a company overview at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 12:45 p.m. ET.
-
BioSpace Movers & Shakers, March 11
3/11/2022
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers -
Frontier Medicines Announces Oral Presentation on Dual-Acting Inhibitors of the Active and Inactive Forms of KRAS G12C at the American Association for Cancer Research (AACR) Annual Meeting
3/9/2022
Frontier Medicines Corporation announced the company will have an oral presentation entitled, “Discovery of Novel Dual-Acting KRASG12C Inhibitors that Target Both the Active and Inactive Forms of the Protein” at the American Association for Cancer Research Annual Meeting taking place April 8-13, 2022 in New Orleans, LA.
-
Frontier Medicines Announces Renowned Physician Scientist Piro Lito, M.D., Ph.D., Joins Scientific Advisory Board
2/8/2022
Frontier Medicines Corporation announced Piro Lito, M.D., Ph.D., associate member and attending physician at Memorial Sloan Kettering Cancer Center, has joined its scientific advisory board.
-
Frontier Medicines Announces Advancement of First Program Under Global Partnership with AbbVie
1/10/2022
Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthroughs against otherwise undruggable disease-causing targets, announced the first target for the development of a small molecule inhibitor is advancing into the lead generation phase under the company’s global partnership with AbbVie.
-
Frontier Medicines to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/5/2022
Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthroughs against otherwise undruggable disease-causing targets, today announced that Chris Varma, Ph.D., Frontier’s co-founder, chairman, and CEO, will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference.
-
BioSpace Movers & Shakers, Nov. 19
11/19/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Avilar Therapeutics officially joined the game with $60 million in seed financing from RA Capital Management.
-
Money on the Move: July 14 – 21
7/21/2021
More money means more progress for potentially life-saving therapies. Here's a peek at some biopharma companies adding to their books this week. -
Frontier Medicines will support the continued development of the company’s chemoproteomics drug discovery program, including lead asset, an inhibitor of KRASG12C.
-
Frontier Medicines Raises $88.5 Million Series B Financing to Advance Precision Oncology and Targeted Protein Degradation Pipeline
7/19/2021
Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthroughs against otherwise undruggable disease-causing targets, announced the closing of an $88.5 million Series B financing round.